ARTICLE | Clinical News
LJP 1082: Began Phase I/II trial
September 17, 2001 7:00 AM UTC
La Jolla Pharmaceutical Co. (LJPC), San Diego, Calif. Product: LJP 1082 Business: Autoimmune/Inflammation Therapeutic category: Immune modulation Target: Antibodies against beta 2 glycoprotein Descr...